CAMBRIDGE, Md. and LONDON, Aug. 26, 2020 (GLOBE NEWSWIRE) — OS Therapies, and late-stage clinical research biotechnology company focused on Osteosarcoma and other solid tumors today announced the co-exclusive licensing of BlinkBio’s novel Si-Linker and Cassette Payload technologies, and exclusive licensing of the BlinkBio technology to target Folate Receptor Alpha (FRα) for tumors and other targeted diseases.
{iframe}https://www.biospace.com/article/releases/os-therapies-to-develop-blinkbio-next-generation-antibody-drug-conjugate-adc-technology-blinkbio-ceo-colin-goddard-joins-os-therapies-board/{/iframe}